Review of 2008: Next-gen DESs bid to upset the status quo
This article was originally published in Clinica
In 2008, two new drug-eluting stents (DESs) were launched onto the US market, making a total of four different products available to US-based cardiologists. The launches of these devices – Medtronic's Endeavor in February and, in July, Abbott's Xience V – came as confirmation, if it were needed, of the cardinal significance of DES technology. Up-and-coming firms, unable to challenge standard DESs, are aiming to displace these entrenched products by making them technologically obsolete.
You may also be interested in...
Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.
Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.
Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.